Description

Rybrevant® (amivantamab)

Targeted therapy for specific forms of non-small cell lung cancer

Overview

Rybrevant® (amivantamab) is a prescription medication designed to treat certain adults with non-small cell lung cancer (NSCLC) whose tumors have specific genetic alterations in the EGFR gene.

It is a bispecific antibody that targets both EGFR (epidermal growth factor receptor) and MET (mesenchymal-epithelial transition factor) pathways, which can contribute to tumor growth and survival.

---

Indication

Rybrevant® is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with:

• EGFR exon 20 insertion mutations
• Disease progression on or after platinum-based chemotherapy

Use is based on confirmed genetic testing of the tumor.

---

How Rybrevant Works

Rybrevant® is a bispecific antibody that binds to two key cancer-driving receptors:

• EGFR: involved in cell growth and division
• MET: involved in tumor cell survival and resistance pathways

By blocking these pathways, Rybrevant® helps inhibit cancer cell growth and may help slow disease progression.

---

Administration

Rybrevant® is given as an intravenous (IV) infusion in a healthcare setting under the supervision of a qualified healthcare professional.

Key points:

• Initial doses may take longer due to step-up dosing
• Premedication may be given to reduce infusion-related reactions
• Treatment schedule is determined by a healthcare provider

---

Important Safety Information

Infusion-Related Reactions

Infusion-related reactions are common, especially during the first dose. Symptoms may include:

• Fever or chills
• Nausea
• Shortness of breath
• Flushing or low blood pressure

Patients are closely monitored during infusion.

---

Other Possible Side Effects

Common side effects may include:

• Rash
• Nail changes
• Fatigue
• Swelling in the hands or feet
• Constipation or diarrhea

Serious side effects may occur. Patients should contact their healthcare provider if symptoms worsen or are severe.

---

Warnings & Precautions

Rybrevant® should be used with caution in patients with:

• History of severe infusion reactions
• Lung or breathing problems
• Skin reactions requiring medical attention

Regular monitoring is recommended during treatment.

---

Genetic Testing Matters

Treatment with Rybrevant® requires confirmation of EGFR exon 20 insertion mutations. Molecular testing helps ensure the right treatment is matched to the right patient.

---

Patient Support & Information

Patients receiving Rybrevant® may have access to:

• Treatment guidance resources
• Infusion support programs
• Educational materials about NSCLC and genetic testing

Speak with a healthcare provider for available support options.

---

Talk to Your Doctor

If you or a loved one has been diagnosed with NSCLC, ask your healthcare provider about biomarker testing and whether Rybrevant® may be an appropriate treatment option.

---